Cantor Fitzgerald Predicts Metsera FY2026 Earnings

Metsera, Inc. (NASDAQ:MTSR - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Metsera in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings per share of ($3.81) for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock.

A number of other research firms have also recently commented on MTSR. Guggenheim lifted their target price on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research note on Tuesday. Evercore ISI started coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an "outperform" rating for the company. Finally, Bank of America started coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a "buy" rating and a $38.00 target price for the company.

Metsera Stock Down 15.0%

MTSR stock traded down $5.20 during trading on Wednesday, reaching $29.38. The company had a trading volume of 809,806 shares, compared to its average volume of 909,801. The business has a 50-day simple moving average of $24.39. Metsera has a twelve month low of $12.30 and a twelve month high of $37.99.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.

Hedge Funds Weigh In On Metsera

A number of institutional investors have recently bought and sold shares of the business. Alphabet Inc. purchased a new position in shares of Metsera during the 1st quarter valued at approximately $135,059,000. T. Rowe Price Investment Management Inc. purchased a new position in shares of Metsera during the 1st quarter valued at approximately $78,748,000. Wellington Management Group LLP purchased a new position in shares of Metsera during the 1st quarter valued at approximately $65,382,000. Alpha Wave Global LP purchased a new position in shares of Metsera during the 1st quarter valued at approximately $64,894,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of Metsera during the 1st quarter valued at approximately $42,395,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.